Table 2 Main formulations of TRAIL fusion proteins
Fusion protein | Target | Main effects | Experimental testing | Ref. |
|---|---|---|---|---|
MBOS4:TRAIL | FAP | Increased bioactivity Active targeting | Fibrosarcoma cell lines in vitro | |
CD40ed:TRAILed | CD40 | Increased bioactivity Active targeting | Fibrosarcoma cell lines in vitro | |
scFv425:sTRAIL | EGFR | Increased drug bioavailability Active targeting Absence of side effects | Pharmacokinetic studies in vivo Tumor xenograft model (RCC) in vivo | |
Increased antitumor activity | Hematologic and solid tumor cell lines in vitro | |||
scFvCD19:sTRAIL | CD19 | Active targeting Absence of side effects Increased antitumor activity | Hematologic tumor cell lines and B-CLL primary cells in vitro Tumor xenograft model (B-ALL) in vivo | |
scFvCD33:sTRAIL | CD33 | Active targeting Increased antitumor activity | Hematologic tumor cell lines and AML primary cells in vitro | |
Anti-MCSP:TRAIL | MCSP | Active targeting Absence of side effects Increased antitumor activity | Melanoma cell lines and normal primary cells in vitro Tumor xenograft model (melanoma) in vivo | |
DbaEGFR-scTRAIL | EGFR | Active targeting Absence of side effects Increased antitumor activity | HCC and CRC cell lines in vitro Tumor xenograft model (CRC) in vivo | |
Anti-CD3:TRAIL K12:TRAIL | CD3 CD7 | Enhanced T-cell activity Increased antitumor activity | Hematologic, solid tumor cell lines and tumor primary cells in vitro Tumor xenograft model (CRC) in vivo | |
scFvCD70:TRAILmutRs | CD70 | Increased bioactivity Active targeting | Hematologic and solid tumor cell lines in vitro | |
scFv:G28-TRAIL | CD40 | Increased bioactivity Active targeting Induction of DC maturation | Fibrosarcoma cell lines in vitro | |
MSC.scFvCD20-sTRAIL | CD20 | Active targeting Absence of side effects Increased antitumor activity | Hematologic tumor cell lines and normal primary cells in vitro Tumor xenograft model (NHL) in vivo | |
CLL1:TRAIL | CLL1 | Enhanced T-cell activity Increased antitumor activity Absence of side effects | Hematologic and solid tumor cell lines in vitro | |
RGD:TRAIL | Integrins | Active targeting Increased antitumor activity | BC and CRC cell lines in vitro Tumor xenograft model (NHL) in vivo | |
scTRAIL: Fc (APG350) | — | Increased antitumor activity | Several cell lines in vitro Tumor xenograft model (CRC) in vivo | |
scFv-EHD2-scTRAIL | — | Increased antitumor activity Active targeting | Several cell lines in vitro Tumor xenograft model (CRC) in vivo | |
FN14:TRAIL | TWEAK | Increased antitumor activity Absence of side effects | HCC cell lines in vitro Tumor xenograft model (HCC) in vivo | |
Increased anti-inflammatory effect | Multiple sclerosis experimental model in vivo |
